AVR118

IN THIS SECTION...
AVR118
Clinical Development Program
Potential Market

AVR118
AVR118 represents a new type of biopolymer chemistry that also possesses novel immunomodulator activity. This non-toxic peptide-nucleic acid, which to date has shown no indication of human toxicity, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papilloma virus and to dampen aberrant autoimmune-type inflammatory responses.

AVR118 is being studied for the promise shown in its ability to mitigate the toxic side effects of other drugs (including those used to treat HIV infection and chemotherapeutic drugs employed in the treatment of cancers); for its ability to stimulate the immune system to attack tumor cells (especially those cancer cells that have been damaged by chemotherapeutic agents) and for its ability to treat cachexia (wasting) in patients with AIDS or cancer.

- Advanced Viral has a patent on the preparation of a therapeutic composition of AVR118.

- AVR118 belongs to the chemical class of peptide nucleic acids (PNAs).

- Advanced Viral holds ten patents related to AVR118 that cover such uses as: the topical treatment of skin disease and eye afflictions including genital herpes and shingles; treatment of basal cell carcinoma; treatment of anemia associated with chronic renal failure, chemotherapy and HIV therapy; combination therapy for HIV; treatment of lupus; and treatment of rheumatoid arthritis.

- In addition to issued patents, Advanced Viral has applications for approximately 20 additional patents related to AVR118, and continues to submit applications for additional patents as appropriate.

The Company is currently targeting therapeutic uses of AVR118 that may allow the Company to take advantage of FDA programs for accelerated drug approvals.

Back to This is ADVR